<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332213</url>
  </required_header>
  <id_info>
    <org_study_id>2914</org_study_id>
    <secondary_id>LZP Nr. 2014.10-5</secondary_id>
    <nct_id>NCT02332213</nct_id>
  </id_info>
  <brief_title>Volatile Markers in Digestive Cancer</brief_title>
  <acronym>VOLGACORE</acronym>
  <official_title>Volatile Marker Testing for Digestive Cancer and Precancerous Lesion Detection, Evaluation of Confounding Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Latvia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Digestive Diseases Centre Gastro (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riga East University Hospital (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic Histology Laboratory (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JLM Innovation GmbH (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Latvia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to determine the potential of volatile marker testing for identification
      of gastrointestinal cancers (in particular - colorectal and gastric cancers), the related
      precancerous lesions in the stomach and colon.

      The study will be addressing the role of confounding factors, including lifestyle factors,
      diet, smoking as well as addressing the potential role of microbiota in the composition of
      exhaled volatile markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with established disease (cancer, precancerous lesions) as well as patients
      investigated for the lesions and having been documented lack of the lesions will be enrolled
      to the study at clinical sites in Europe (Latvia, Lithuania). In addition, group of persons
      from general population at average risk for developing the target disease will be also
      enrolled.

      Testing of volatile markers will be conducted by one of two methods: 1) gas chromatography
      coupled to mass spectroscopy (GS-MS) and 2) nanosensor technology.

      Volunteers (including patients with established disease) will be enrolled prior the removal
      of the target lesion (e.g. surgery for cancer or polypectomy in the case of a polyp).

      The study will be conducted by utilizing the experience of institutions in the European Union
      and Israel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of nanoarray sensor testing to detect target lesions</measure>
    <time_frame>At the time of breath sampling</time_frame>
    <description>Sensitivity, specificity, overall accuracy of nanoarray sensor testing for VOCs to detect the target lesions in the blinded analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VOCs differentiating the study groups</measure>
    <time_frame>At the time of breath sampling</time_frame>
    <description>List of VOCs assayed by GC-MS with statistical difference between the study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of characteristic VOC pattern in risk age groups</measure>
    <time_frame>At the time of sampling</time_frame>
    <description>List of characteristic VOCs in general population at risk for developing gastrointestinal cancer, including analysis of confounding factors, e.g. dietary habits, smoking, and profession.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOC pattern changes following treatment</measure>
    <time_frame>At baseline and every 6 months within 3 year period</time_frame>
    <description>Significant change in VOC content before and following treatment (surgery, medical therapy, combined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups of gastrointestinal microbiota correlating to VOCs</measure>
    <time_frame>At the time of sampling</time_frame>
    <description>List of gastrointestinal microbiota groups (phylum/genus level) with positive correlation to particular VOCs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VOC pattern changes following intervention to microbiota</measure>
    <time_frame>At baseline and following the intervention (1 week, 1 month)</time_frame>
    <description>Significant change in VOC content before and following intervention upon microbiome (antibiotic intake, colon cleansing)</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastric microbiome changes following intervention to microbiota</measure>
    <time_frame>At baseline and 3 years after intervention</time_frame>
    <description>Significant change in gastric microbiome (phyla, genera) before and following intervention upon microbiome (antibiotic intake)</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal microbiome in cancer patients</measure>
    <time_frame>At the time of sampling</time_frame>
    <description>Significant differences in the composition of gastric and colonic microbiome (phyla, genera) in cancer patients, patients with precancerous lesions and controls</description>
  </other_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Adenoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Peptic Ulcer Disease</condition>
  <condition>Atrophic Gastritis</condition>
  <condition>Intestinal Metaplasia</condition>
  <condition>H.Pylori Infection</condition>
  <condition>Normal Control</condition>
  <condition>Average-risk General Population</condition>
  <arm_group>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <description>Patients with histologically confirmed colorectal cancer (adenocarcinoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Colorectal high-risk lesions</arm_group_label>
    <description>Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) sizeâ‰¥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Colorectal low-risk adenoma</arm_group_label>
    <description>Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Group of control (colorectal)</arm_group_label>
    <description>Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5. Gastric cancer</arm_group_label>
    <description>Patients with histologically confirmed gastric cancer (adenocarcinoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6. Gastric dysplasia</arm_group_label>
    <description>Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7. High-risk gastric lesions</arm_group_label>
    <description>Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8. Normal and low-risk gastric lesions</arm_group_label>
    <description>Staged 0-III according to OLGIM. Dysplasia should be excluded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9. Average risk population</arm_group_label>
    <description>Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breath sampling for volatile marker detection</intervention_name>
    <description>Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology</description>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <arm_group_label>2. Colorectal high-risk lesions</arm_group_label>
    <arm_group_label>3. Colorectal low-risk adenoma</arm_group_label>
    <arm_group_label>4. Group of control (colorectal)</arm_group_label>
    <arm_group_label>5. Gastric cancer</arm_group_label>
    <arm_group_label>6. Gastric dysplasia</arm_group_label>
    <arm_group_label>7. High-risk gastric lesions</arm_group_label>
    <arm_group_label>8. Normal and low-risk gastric lesions</arm_group_label>
    <arm_group_label>9. Average risk population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper endoscopy with biopsies</intervention_name>
    <description>Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing</description>
    <arm_group_label>5. Gastric cancer</arm_group_label>
    <arm_group_label>6. Gastric dysplasia</arm_group_label>
    <arm_group_label>7. High-risk gastric lesions</arm_group_label>
    <arm_group_label>8. Normal and low-risk gastric lesions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy with biopsies or lesion removal when required</intervention_name>
    <description>Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing</description>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <arm_group_label>2. Colorectal high-risk lesions</arm_group_label>
    <arm_group_label>3. Colorectal low-risk adenoma</arm_group_label>
    <arm_group_label>4. Group of control (colorectal)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma/serum sampling</intervention_name>
    <description>Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination</description>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <arm_group_label>2. Colorectal high-risk lesions</arm_group_label>
    <arm_group_label>3. Colorectal low-risk adenoma</arm_group_label>
    <arm_group_label>4. Group of control (colorectal)</arm_group_label>
    <arm_group_label>5. Gastric cancer</arm_group_label>
    <arm_group_label>6. Gastric dysplasia</arm_group_label>
    <arm_group_label>7. High-risk gastric lesions</arm_group_label>
    <arm_group_label>8. Normal and low-risk gastric lesions</arm_group_label>
    <arm_group_label>9. Average risk population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Faecal sample acquisition</intervention_name>
    <description>Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis</description>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <arm_group_label>2. Colorectal high-risk lesions</arm_group_label>
    <arm_group_label>3. Colorectal low-risk adenoma</arm_group_label>
    <arm_group_label>4. Group of control (colorectal)</arm_group_label>
    <arm_group_label>5. Gastric cancer</arm_group_label>
    <arm_group_label>6. Gastric dysplasia</arm_group_label>
    <arm_group_label>7. High-risk gastric lesions</arm_group_label>
    <arm_group_label>8. Normal and low-risk gastric lesions</arm_group_label>
    <arm_group_label>9. Average risk population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Histological evaluation of the surgery material</intervention_name>
    <description>The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)</description>
    <arm_group_label>1. Colorectal cancer</arm_group_label>
    <arm_group_label>5. Gastric cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled air samples being stored in specific adsorbent media Plasma/serum samples for group
      stratification Faecal samples for occult blood testing and microbiota analysis Biopsy samples
      from stomach and colon
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients (Group 1 and 5) will be predominantly enrolled at the time scheduled for
        surgery, however also patients undergoing diagnostic procedures (endoscopy) will be
        eligible

        Patients without malignant disease but defined colorectal (Groups 2-4) status will be
        predominantly enrolled prior colonoscopy in out-patient settings. Sampling starting from 1
        week after colonoscopy will be allowed if the lesions will not get removed during the index
        endoscopy

        Patients without malignant disease but defined gastric mucosal status (Groups 6-8) status
        will be predominantly enrolled prior upper endoscopy in out-patient settings. Sampling
        starting from 2 days after upper endoscopy will be allowed if the lesions will not get
        removed during the index endoscopy

        Average cancer risk subjects (Group 9) will get enrolled by inviting individuals
        predominantly selected from the lists of general practitioners.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with verifies colorectal cancer (Group 1)

          -  Patients with verified gastric cancer (Group 5)

          -  Patients undergoing colonoscopy due to clinical indications (group 2-4)

          -  Patients undergoing upper endoscopy due to clinical indications (Group 6-8)

          -  Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 9)

          -  Motivation to participate in the study

          -  Physical status allowing volatile marker sampling and other procedures within the
             protocol

          -  Signed consent

        Exclusion Criteria:

          -  Known other active cancer

          -  Ventilation problems, airway obstruction

          -  Unwillingness or inability to co-operate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossam Haick, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technion, Israel Institute for Technology (Israel)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcis Leja, MD, PhD</last_name>
    <phone>+371-29497500</phone>
    <email>marcis.leja@lu.lv</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daiga Santare, MD</last_name>
    <phone>+371-29221107</phone>
    <email>daiga.santare@inbox.lv</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Latvia</name>
      <address>
        <city>Riga</city>
        <zip>LV 1586</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcis Leja, MD, PhD</last_name>
      <phone>+371-29497500</phone>
      <email>marcis.leja@lu.lv</email>
    </contact>
    <contact_backup>
      <last_name>Daiga Santare, MD</last_name>
      <phone>+371-29221107</phone>
      <email>daiga.santare@inbox.lv</email>
    </contact_backup>
    <investigator>
      <last_name>Marcis Leja, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ieva Lasina, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>LT 44307</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Limas Kupcinskas, MD, PhD</last_name>
      <phone>+37068640575</phone>
      <email>likup@takas.lt</email>
    </contact>
    <contact_backup>
      <last_name>Juozas Kupcinskas, MD</last_name>
      <phone>+37068640575</phone>
      <email>j_kupcinskas@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Limas Kupcinskas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juozas Kupcinskas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Latvia</country>
    <country>Lithuania</country>
  </location_countries>
  <reference>
    <citation>Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev. 2014 Mar 7;43(5):1423-49. doi: 10.1039/c3cs60329f. Epub 2013 Dec 4. Review.</citation>
    <PMID>24305596</PMID>
  </reference>
  <reference>
    <citation>Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, Song Q, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD, Leja M, Haick H. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013 Mar 5;108(4):941-50. doi: 10.1038/bjc.2013.44.</citation>
    <PMID>23462808</PMID>
  </reference>
  <reference>
    <citation>Amal H, Leja M, Broza YY, Tisch U, Funka K, Liepniece-Karele I, Skapars R, Xu ZQ, Liu H, Haick H. Geographical variation in the exhaled volatile organic compounds. J Breath Res. 2013 Dec;7(4):047102. doi: 10.1088/1752-7155/7/4/047102. Epub 2013 Nov 1.</citation>
    <PMID>24184568</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 2, 2015</last_update_submitted>
  <last_update_submitted_qc>January 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volatile organic compounds</keyword>
  <keyword>Nanosensor technology</keyword>
  <keyword>GC-MS</keyword>
  <keyword>Breath-testing</keyword>
  <keyword>Digestive cancer</keyword>
  <keyword>Precancerous lesions</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Adenoma</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Atrophic gastritis</keyword>
  <keyword>OLGIM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

